
Llusern Scientific Speeding Up Infection Diagnosis with Welsh Innovation Support
Llusern Scientific is developing rapid diagnostic tests to transform how urinary tract infections are diagnosed and treated.
With targeted support from the Welsh Government's Innovation team, the company, which is based at Cardiff Edge Business Park, is bringing its first product to market. It is set to pave the way for faster diagnosis, better patient outcomes and reduced antibiotic misuse.
Established in 2020 as a spin-out from the University of South Wales, the company set out to address a major health challenge. Urinary infections affect more than 100 million people worldwide each year. Its portable, easy-to-use molecular diagnostic device delivers accurate results within 35 minutes, giving clinicians fast and reliable information.
The company has now announced that it has been awarded ISO 13485 certification for its Lodestar DX testing system, a rapid molecular diagnostic platform for urinary tract infections (UTIs).
Dr Emma Hayhurst, co-founder and CEO of Llusern Scientific, said:
'When we founded Llusern Scientific, we were on a mission to make a positive difference in healthcare by developing a point-of-care diagnostic that would enable us to improve antimicrobial stewardship. Achieving ISO 13485 certification is a major milestone in our mission because it demonstrates that we have built a manufacturing facility to world-class standards.
'Not only does our Lodestar UTI testing system help a clinician decide whether or not to prescribe an antibiotic, but it will also identify the bacterial cause of the UTI. This enables clinicians to quickly target the right bug with the right treatment to save lives. Now we have ISO 13485 certification, our next goal is to achieve IVDR certification to further expand the market potential for our innovative molecular diagnostic globally.'
There are more than 400 million UTI cases globally each year, of which around 90% are women. According to the Sepsis Trust approximately 15-30% of sepsis cases are caused by a UTI. Research has shown that antibiotics are overprescribed by as much as two times for UTIs leading to them being a major driver of antimicrobial resistance (AMR). As well as providing guidance on the best treatment option, Lodestar DX also provides a clear 'rule-out' decision where antibiotics are not necessary, helping to reduce AMR through antibiotic stewardship.
ISO 13485 certification is a crucial regulatory step for marketing medical devices globally, as it demonstrates that a manufacturer has a robust Quality Management System in place, showing commitment to patient safety, regulatory compliance, and consistent product quality.
Llusern is preparing for commercial launches across India and the Middle East and North Africa region this year, and the US in 2026.
The company has received a range of targeted support from the Welsh Government's Innovation team, including SMART Flexible Innovation Support (SFIS), expert design assistance and intellectual property (IP) strategy development—each playing a vital role in advancing the technology and preparing for commercial scale-up.
Initial SFIS support in early 2024 enabled the team to develop a clear innovation plan, setting out priorities for product improvements, new clinical applications and growth. A second SFIS award in September 2024 has since supported the delivery of this plan, while design and IP interventions have strengthened its route to market.
As a result, Welsh Government innovation support has helped Llusern Scientific to: Enhance its existing diagnostic platform, making it suitable for use in a wider range of clinical settings.
Develop a new unique test panel design, addressing contamination risks and improving ease of use for non-laboratory settings.
Strengthen its IP portfolio through a comprehensive audit and actionable recommendations, boosting investor confidence.
Expand research and development facilities at Cardiff Edge Business Park.
Advance collaborations with Public Health Wales and NHS partners, supporting clinical validation and real-world evidence generation.
While Agile Cymru funding has provided valuable opportunities to explore international markets, the company's core innovation progress has been driven by targeted support from the Welsh Government's Innovation team.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Scotsman
10 hours ago
- Scotsman
Webinar welcomes national standards body for support on navigating new legislation
A free webinar has encouraged medical device innovators to learn more about new Post-Market Surveillance (PMS) legislation and how to successfully navigate it. Sign up to our Scotsman Money newsletter, covering all you need to know to help manage your money. Sign up Thank you for signing up! Did you know with a Digital Subscription to The Scotsman, you can get unlimited access to the website including our premium content, as well as benefiting from fewer ads, loyalty rewards and much more. Learn More Sorry, there seem to be some issues. Please try again later. Submitting... Hosting the educational session on Wednesday, June 25 – entitled ' The new Post-Market Surveillance legislation for medical devices - what you need to know' – formal NHS Scotland partner InnoScot Health believes it was a key opportunity to better understand the changes for Great Britain. The changes are intended to improve the safety of medical devices – including in vitro diagnostics (IVD) and active implantable devices – while providing certainty for manufacturers. Advertisement Hide Ad Advertisement Hide Ad Part of wider regulatory reform, the amended regulation will, the Medicines and Healthcare products Regulatory Agency (MHRA) says, 'introduce clearer and more risk-proportionate PMS requirements'. Head of Innovation, Robert Rea, InnoScot Health The 'lunch and learn' webinar was presented by Head of Regulatory Affairs Elaine Gemmell, who provided an overview of the complexities of the current landscape and outlined why it is vital to receive professional advice in order to navigate it successfully. She was joined by guest speakers from The British Standards Institution (BSI) – Damon Williams, Sales Manager – Medical Devices, UK & Ireland, and Umar Butt, Business Development Manager, North UK and Ireland. The national standards body of the United Kingdom, BSI is recognised through a Memorandum of Understanding with the UK Government, producing technical standards on a wide range of products and services. Advertisement Hide Ad Advertisement Hide Ad They spoke on the similarities and key deviations the UK PMS regulation has from EU MDR/IVDR and anticipated changes. User (UGC) Submitted Elaine said: 'Our June webinar was an opportunity to gain a more in-depth understanding of what is crucial new legislation for medical device manufacturers. 'Never more have we needed transformative approaches to healthcare for better patient outcomes, and new medical device breakthroughs are a key driver in realising that goal. 'But clearer, more robust post-market surveillance requirements are necessary to improve safety for both patients and public alike, and in greater alignment with international standards. Advertisement Hide Ad Advertisement Hide Ad 'In response, we now have an important amendment this month and manufacturers are advised to learn more. 'We believe attendees found it useful and instructive in taking practical steps.' The webinar was rounded off by an opportunity to ask questions of the speakers. The medical device industry has experienced unprecedented growth over recent years, and changes to the regulatory landscape mean it is vital innovators get the right advice, support and signposting to develop effective and innovative healthcare products.

South Wales Argus
19 hours ago
- South Wales Argus
RSPCA issues advice for poultry keepers after bird flu cases
The RSPCA is calling on poultry keepers in Wales to follow biosecurity advice after two cases of highly pathogenic avian influenza were confirmed in Pembrokeshire and Wrexham— the first outbreaks in the country in two years. Kate Parkes, poultry expert at the RSPCA, said: "It's rarer at this time of year to see outbreaks of avian influenza but sadly not uncommon – as we have now seen in west and north Wales." Welsh Government has introduced 3km protection zones and 10km surveillance zones around the affected areas. A mandatory housing order now requires all farmed and pet poultry within the zones to be kept indoors. The RSPCA is also encouraging owners to keep their birds 'hentertained' with indoor enrichment. Ms Parkes said: "Having nothing to do can lead to boredom, stress and contribute to problems such as feather pecking." Perches, straw bales and puzzle feeders can keep poultry occupied.


Business News Wales
a day ago
- Business News Wales
New Bereavement Support Service Launches for Over 70s in Dyfed and Powys
A new bereavement support service for older adults has launched across the Dyfed and Powys areas. Delivered by Age Cymru Dyfed and Age Cymru Powys, the new service has been made possible by funding from the Welsh Government National Bereavement Support Grant 2025. The service is an early intervention approach, with the aim of reducing barriers for older adults within bereavement services. It addresses critical gaps in initial bereavement support for people aged 70 and over — a group especially vulnerable to isolation and crisis following the loss of a loved one, particularly in rural and underserved areas. The Office for National Statistics estimates over a quarter of bereavement support needs for older adults in Wales goes unmet and the charity says this leaves many older adults feeling unprepared and isolated, with many unable to cope. This new project offers early, compassionate and equitable access to make bereavement pathways clear and accessible for the over 70s age group within Dyfed and Powys. Practical support will be available, both face-to-face and remotely, helping to build resilience, reduce isolation, and ease pressure on health and social care systems. The initiative will also contribute to a growing evidence base to help shape future bereavement services across Wales.